BPT Crunch

Companies on the Cutting Edge of Healthcare Innovations

back to Marketplace

Landos Biopharma

Landos Biopharma logo

United States of America based
$173 M

Landos Biopharma, Inc. is an emerging biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases. Landos’ lead clinical asset, BT-11, is a novel, locally-acting small molecule targeting inflammatory bowel disease (IBD) that is expected to enter clinical testing for Crohn’s disease in 2018. Landos also has a robust pipeline of compounds for other autoimmune diseases. Landos is headquartered in Blacksburg, VA.

Unclearative colit


AI Companies (Drug Discovery)  

R&D Platform


LANCE platform
Immunometabolic Targets

Read more


Clinical  |  Visit website

Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel oral small-molecule therapeutics for patients with autoimmune diseases, today announced a research collaboration with the Icahn School of Medicine at Mount Sinai to conduct a Phase 2 trial of omilancor, Landos’ novel, orally administered, gut-restricted LANCL2 agonist, in patients with moderate-to-severe Crohn’s disease (CD).




No services posted yet